Abacus Health Products (OTCMKTS:ABAHF – Get Free Report) and Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.
Institutional & Insider Ownership
86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Abacus Health Products and Milestone Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Abacus Health Products | N/A | N/A | N/A | N/A | N/A |
| Milestone Pharmaceuticals | $1.78 million | 79.21 | -$63.06 million | ($0.68) | -1.67 |
Abacus Health Products has higher earnings, but lower revenue than Milestone Pharmaceuticals.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Abacus Health Products and Milestone Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abacus Health Products | 0 | 0 | 0 | 0 | 0.00 |
| Milestone Pharmaceuticals | 1 | 1 | 3 | 1 | 2.67 |
Milestone Pharmaceuticals has a consensus price target of $7.25, suggesting a potential upside of 538.77%. Given Milestone Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Abacus Health Products.
Profitability
This table compares Abacus Health Products and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Abacus Health Products | N/A | N/A | N/A |
| Milestone Pharmaceuticals | N/A | -339.33% | -61.79% |
Summary
Milestone Pharmaceuticals beats Abacus Health Products on 7 of the 9 factors compared between the two stocks.
About Abacus Health Products
Abacus Health Products, Inc. manufactures and sells over-the-counter (OTC) topical formulations infused with cannabidiol (CBD) extracted from hemps. The company offers CBD CLINIC line of products for relief from acute musculoskeletal and joint pain, which includes analgesic ointments, creams, and pain sticks, as well as analgesic massage oils. It also provides CBDMEDIC line of products, such as sport ointments and pain sticks, back and neck ointments, arthritis hand creams and ointments, and massage therapy oils, as well as ointments and pain sprays for muscles and joints. The company offers its CBD CLINIC products to registered health practitioners, including chiropractors, acupuncturists, massage and physical therapists, naturopaths, and osteopaths; and CBDMEDIC products directly to consumers through retail pharmacy chains and fitness locations, as well as online through the e-commerce platform. In addition, it is involved in developing a pipeline of other OTC CBD products addressing additional medical indications and the health and wellness sectors. The company is headquartered in Toronto, Canada. Abacus Health Products, Inc. is a subsidiary of Aidance Skincare & Topical Solutions, LLC.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Receive News & Ratings for Abacus Health Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abacus Health Products and related companies with MarketBeat.com's FREE daily email newsletter.
